Is Merck a Better Buy After Announcing Spinoff?

When companies focus on their strengths and core competencies, it can make them better investments. That's what Merck (NYSE: MRK) is hoping will happen, as the company announced on Feb. 5 that it will be spinning off its women's health business along with legacy brands and biosimilars into a new company as it attempts to focus on "key growth pillars:" oncology, vaccines, animal health, and hospital.